natgillin/translations-raw huggingface dataset:
Pancreatitis * In the FIELD study, a randomised placebo-controlled trial performed in 9795 patients with type 2 diabetes mellitus, a statistically significant increase in pancreatitis cases was observed in patients receiving fenofibrate versus patients receiving placebo (0.8% versus 0.5%; p=0.031).
Pankreatitis * U randomiziranom, placebom kontroliranom ispitivanju "FIELD", provedenom na 9795 bolesnika s šećernom bolešću tipa 2, opažen je statistički značajno povećanje broja slučajeva pankreatitisa kod bolesnika koji su primali fenofibrat naspram bolesnika koji su primali placebo (0,8% naspram 0,5%; p=0,031).
• digestive disturbances (stomach pain, nausea, vomiting, diarrhoea and flatulence)
• poremećaji probave (bol u trbuhu, mučnina, povraćanje, proljev i vjetrovi)
It is given to lower triglycerides and increase the good cholesterol (HDL cholesterol) in patients whose bad cholesterol (LDL cholesterol) is already controlled with simvastatin alone in a dose of 40 mg.
Daje se radi snižavanja triglicerida i povisivanja dobrog kolesterola (HDL kolesterol) u pacijenata kod kojih se loš kolesterol (LDL kolesterol) već kontrolira samim simvastatinom u dozi od 40 mg.
Statin monotherapy
Monoterapija statinom
In the pre-specified subgroup of dyslipidaemic patients, defined as those in the lowest tertile of HDL-C (≤ 34 mg/dl or 0.88 mmol/L) and highest tertile of TG (≥ 204 mg/dl or 2.3 mmol/L) at baseline, fenofibrate plus simvastatin therapy demonstrated a 31% relative reduction compared to simvastatin monotherapy for the composite primary outcome (hazard ratio [HR] 0.69, 95% CI 0.49-0.97, p=0.03; absolute risk reduction: 4.95%).
U unaprijed definiranoj podskupini bolesnika s dislipidemijom, definiranih kao oni u najnižoj trećini HDL-C (≤34 mg/dl ili 0,88 mmol/l) i najvišoj trećini TG (≥204 mg/dl ili 2,3 mmol/l) kao početnoj vrijednosti, terapija fenofibrat plus simvastatin pokazala je relativno sniženje od 31% u usporedbi s monoterapijom simvastatinom za složeni primarni ishod (omjer rizika [HR] 0,69; 95% CI 0,49-0,97, p=0,03; apsolutno smanjenje rizika: 4,95%).
Statin 6 weeks run-in
6-tjedno uvođenje statina
Inhibitors of Breast Cancer Resistant Protein (BCRP) Concomitant administration of medicinal products that are inhibitors of BCRP, including products containing elbasvir or grazoprevir, may lead to increased plasma concentrations of simvastatin and an increased risk of myopathy (see sections 4.2 and 4.4).
Inhibitori proteina rezistencije na rak dojke (BCRP) Istodobna primjena lijekova koji su inhibitori BCRP-a, uključujući lijekove koji sadrže elbasvir ili grazoprevir, može dovesti do povećane koncentracije simvastatina u plazmi te povećanog rizika od miopatije (vidjeti dijelove 4.2 i 4.4).
Grapefruit juice inhibits CYP 3A4.
Sok od grejpa inhibira CYP 3A4.
Hypersensitivity syndrome *** An apparent hypersensitivity syndrome has been reported rarely which has included some of the following features: angioedema, lupus-like syndrome, polymyalgia rheumatica, dermatomyositis, vasculitis, thrombocytopenia, eosinophilia, erythrocyte sedimentation rate (ESR) increased, arthritis and arthralgia, urticaria, photosensitivity, fever, flushing, dyspnoea and malaise.
Sindrom preosjetljivosti *** Rijetko je prijavljivan očevidan sindrom preosjetljivosti, koji je uključivao neke od sljedećih značajki: angioedem, sindrom nalik lupusu, reumatska polimialgija, dermatomiozitis, vaskulitis, trombocitopenija, eozinofilija, povećanje brzine sedimentacije eritrocita (ESR), artritis i artralgija, urtikarija, fotosenzitivnost, vrućica, crvenilo uz osjećaj vrućine, dispneja i malaksalost.
Reversible elevations in serum creatinine have been reported in patients receiving fenofibrate monotherapy or co-administered with statins.
Reverzibilna povišenja serumskog kreatinina prijavljena su u bolesnika koji su primali fenofibrat kao monoterapiju ili uz istodobnu primjenu statina.
Fenofibrate plus simvastatin therapy did not show any significant differences compared to simvastatin monotherapy in the composite primary outcome of non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death (hazard ratio [HR] 0.92, 95% CI 0.79-1.08, p = 0.32; absolute risk reduction: 0.74%).
Terapija fenofibrat plus simvastatin nije pokazala bilo kakve značajne razlike u usporedbi s monoterapijom simvastatinom u smislu primarnog složenog ishoda, koji je obuhvaćao nefatalni infarkt miokarda, nefatalni moždani udar i kardiovaskularnu smrt (omjer rizika [HR] 0,92; 95% CI 0,79-1,08, p=0,32; apsolutno smanjenje rizika: 0,74%).
Interstitial lung disease not known
Intersticijska bolest pluća nepoznato
Muscle disorders (e.g. myalgia, myositis, muscular spasms and weakness)
Mišićni poremećaji (npr. mijalgija, miozitis, grčevi i slabost mišića)
The combination of fenofibrate 145 mg with simvastatin 20 mg demonstrated statistically significant superiority on apoA1 increase and fibrinogen decrease compared to simvastatin 40 mg.
Kombinacija 145 mg fenofibrata i 20 mg simvastatina pokazala je statistički značajnu superiornost na povišenje apoA1 te sniženje fibrinogena u usporedbi s 40 mg simvastatina.
Treatment emergent adverse reactions reported in patients receiving co-administration of fenofibrate and simvastatin occurring are listed below by system organ class and frequency.
Nuspojave koje su prijavljivane tijekom liječenja u bolesnika koji su istodobno primali fenofibrat i simvastatin navedeni su u nastavku prema klasifikaciji organskih sustava i učestalosti.
Fibrinogen (g/L) *Treatment Comparison: difference between the LS Means for Feno 145 + Simva 20 and Simva 40, as well as the associated 95% confidence interval
Fibrinogen (g/l) *Usporedba liječenja: razlika između srednjih vrijednosti LS za feno 145 + simva 20 i simva 40, kao i odgovarajući 95%-tni interval pouzdanosti (CI).
In patients where the use of systemic fusidic acid is considered essential, statin treatment should be discontinued throughout the duration of fusidic acid treatment.
U bolesnika kod kojih se sistemska primjena fusidatne kiseline smatra neophodnom, potrebno je prekinuti liječenje statinom sve dok traje liječenje fusidatnom kiselinom.
Blood alkaline phosphatase increased rare
Povišenje alkalne fosfataze u krvi rijetko
No unchanged fenofibrate can be detected in the plasma.
Fenofibrat se u plazmi ne može dokazati u nepromijenjenu obliku.
• anticoagulants such as warfarin, fluindione, phenprocoumone or acenocoumarol
• antikoagulanse kao što su varfarin, fluindion, fenprokumon ili acenokumarol (lijekovi za sprečavanje stvaranja krvnih ugrušaka)
This was not significantly different from the 29% (90% CI 22%-35%) reduction in AUC of SVA observed when co-administration was 12 hours apart: simvastatin 40 mg in the evening and fenofibrate 145 mg in the morning.
To nije bilo značajno različito od smanjenja AUC-a SVA-a za 29% (90% CI 22%-35%) koje je opaženo kada je istodobna primjena bila u razmaku od 12 sati: 40 mg simvastatina navečer i 145 mg fenofibrata ujutro.
Your doctor can measure your lipids with a simple blood test. Visit your doctor regularly to keep track of your lipids level.
Redovito posjećujte svog liječnika da biste pratili razine Vaših lipida.
• you have chest pain and are feeling breathless.
• ako imate bol u prsnom košu i osjećate nedostatak zraka.
Concomitant administration of diltiazem and simvastatin caused a 2.7-fold increase in exposure of simvastatin acid, presumable due to inhibition of CYP 3A4.
Istodobna primjena diltiazema i simvastatina uzrokovala je povećanje izloženosti simvastatinskoj kiselini od 2,7 puta, a pretpostavlja se zbog inhibicije CYP 3A4.
These may be signs of a blood clot in the lung
To mogu biti znakovi krvnog ugruška u plućima (plućna embolija)
• you have severe lung disease
• ako imate tešku bolest pluća
• pain, redness or swelling in the legs - these may be signs of a blood clot in the leg (deep vein thrombosis)
• bol, crvenilo ili oticanje nogu - to mogu biti znakovi krvnog ugruška u nozi (duboka venska tromboza)
Constipation, dyspepsia rare
Konstipacija, dispepsija rijetko
Anaemia rare
Anemija rijetko
No preclinical studies have been performed with the fixed dose combination Cholib.
Nisu provedena neklinička ispitivanja s fiksnom kombinacijom doze Choliba.
Complications of cholelithiasis (e.g. cholecystitis, cholangitis, biliary colic etc)
Komplikacije kolelitijaze (npr. kolecistitis, kolangitis, žučna kolika itd.)
Fenofibrate is not a substrate for CYP 3A4.
Fenofibrat nije supstrat za CYP3A4.
• elbasvir or grazoprevir (used to treat hepatitis C virus infection)
• elbasvir ili grazoprevir (koji se upotrebljavaju za liječenje infekcije virusom hepatitisa C).
What you need to know before you take use Cholib
Što morate znati prije nego počnete uzimati Cholib Nemojte uzimati Cholib:
How to store Cholib
Kako čuvati Cholib
Insomnia very rare
Nesanica vrlo rijetko
If treatment with itraconazole, ketoconazole, posaconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with Cholib must be suspended during the course of treatment.
Ako ne možete izbjeći liječenje itrakonazolom, ketokonazolom, pozakonazolom, eritromicinom, klaritromicinom ili telitromicinom, potrebno je obustaviti terapiju Cholibom tijekom trajanja liječenja.
Only anecdotal cases of fenofibrate overdose have been received.
Prijavljeni su nasumični slučajevi predoziranja fenofibratom.
Glycosylated haemoglobin increased not known
Povišenje glikoziliranog hemoglobina nepoznato
TG, LDL-C and HDL-C Percent Change from Baseline to 12 and 24 Weeks Full Analysis Subject Sample
Postotak promjene nakon 12 i 24 tjedna od početne vrijednosti TG, LDL-C i HDL-C Potpuna analiza uzorka ispitanika
Blood creatinine increased: 10% of patient had a creatinine increase from baseline greater than 30 µmol/L with co-administered fenofibrate and simvastatin versus 4.4% with statin monotherapy.
Povišenje kreatinina u krvi: 10% bolesnika imalo je povišenje kreatinina u odnosu na početnu vrijednost veće od 30 µmol/l kada je fenofibrat istodobno primijenjen sa simvastatinom, naspram 4,4% bolesnika na monoterapiji statinom.
Muscle
Mišići
• increase in “glycosylated haemoglobin” and blood glucose levels - markers for blood glucose control in diabetes mellitus - shown in tests
• povišene razine “glikoziliranog hemoglobina” i glukoze u krvi - pokazatelji kod kontrole šećera u krvi u šećernoj bolesti) - pokazuju ih pretrage
• Personal or familial history of hereditary muscular disorders
• Nasljedni mišićni poremećaji u osobnoj ili obiteljskoj anamnezi
Activation of PPAR also induces an increase in the synthesis of apoproteins AI and AII.
Aktivacijom PPARα također se izaziva i sinteza apoproteina A1 i A2.
Such inhibitors include itraconazole, ketoconazole, posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors (e.g. nelfinavir), and nefazodone.
Takvi inhibitori uključuju itrakonazol, ketokonazol, pozakonazol, eritromicin, klaritromicin, telitromicin, inhibitore proteaze HIV-a (npr. nelfinavir) i nefazodon.
• rifampicin (a medicine used to treat tuberculosis).
• rifampicin (lijek koji se koristi za liječenje tuberkuloze).
During clinical trials, 10% of patients had a creatinine increase from baseline greater than 30 µmol/L with co-administered fenofibrate and simvastatin versus 4.4% with statin monotherapy.
Tijekom kliničkih ispitivanja, 10% bolesnika imalo je povišenje kreatinina u odnosu na početnu vrijednost veće od 30 µmol/l kada je fenofibrat istodobno primijenjen uz simvastatin, naspram 4,4% bolesnika na monoterapiji statinom.
In the larger study a reduction of 21% (90% CI 14%-27%) in AUC of SVA was observed after repeated co-administration of simvastatin 40 mg and fenofibrate 145 mg in the evening.
U većem ispitivanju opaženo je smanjenje AUC-a SVA-a za 21% (90% CI 14%-27%) nakon ponovljene istodobne primjene 40 mg simvastatina i 145 mg fenofibrata navečer.
Immune-mediated necrotizing myopathy (IMNM)
Imunološki posredovana nekrotizirajuća miopatija
6.5 Nature and contents of container
6.5 Vrsta i sadržaj spremnika Al/Al blisteri
• rifampicin (a medicine used to treat tuberculosis)
• rifampicin (lijek koji se koristi za liječenje tuberkuloze)
• If you are already being treated and will continue your treatment with: o a fibrate (e.g. gemfibrozil) o a statin (medicines to lower the levels of fats in the blood, e.g. simvastatin, atorvastatin)
• Ako se već liječite i nastavit ćete liječenje s:  fibratom (npr. gemfibrozil)  statinom (lijekovi za snižavanje razina masnoća u krvi, npr. simvastatin, atorvastatin)
Amiodarone, amlodipine, diltiazem and verapamil The risk of myopathy and rhabdomyolysis is increased by concomitant use of amiodarone, amlodipine, diltiazem or verapamil with simvastatin 40 mg per day.
Rizik od miopatije i rabdomiolize povećan je kada se istodobno primjenjuju amiodaron, amlodipin, diltiazem ili verapamil sa simvastatinom 40 mg dnevno.
However reversible hypospermia and testicular vacuolation and immaturity of the ovaries were observed in a repeat-dose toxicity study with fenofibric acid in young dogs.
Međutim, u ispitivanju toksičnosti ponovljene doze s fenofibričnom kiselinom u mladih pasa, opažene su reverzibilna hipospermija i testikularna vakuolizacija te nezrelost jajnika.
Fenofibrate is a mild to moderate inhibitor of CYP 2C9 and a weak inhibitor of CYP 2C19 and CYP 2A6.
Fenofibrat i simvastatin nisu inhibitori CYP 2D6, CYP 2E1 ili CYP 1A2. Fenofibrat je blagi do umjeren inhibitor CYP 2C9 i slabi inhibitor CYP 2C19 i CYP 2A6.
One film-coated tablet contains 160.1 mg of lactose (as monohydrate), 145 mg of sucrose, 0.7 mg of lecithin (derived from soya bean (E322)) and 0.17 mg of sunset yellow FCF (E110).
Jedna filmom obložena tableta sadrži 160,1 mg laktoze (u obliku hidrata), 145 mg saharoze, 0,7 mg lecitina (iz soje (E322)) i 0,17 mg bojila sunset yellow FCF (E110).
Prolongation of the gestation period and difficulties during delivery were observed at high doses.
Pri visokim dozama opaženi su produljenje gestacijskog razdoblja i teškoće pri okotu.
Supportive study
Potporno ispitivanje
Anaphylaxis very rare
Zatajenje jetre vrlo rijetko
After the first 12 weeks of treatment, the combination of fenofibrate 145 mg and simvastatin 20 mg showed superiority over simvastatin 40 mg for TG reduction and HDL-C increase but did not meet the criteria for non-inferiority on LDL-C.
Nakon prvih 12 tjedana liječenja, kombinacija 145 mg fenofibrata i 20 mg simvastatina pokazala je superiornost u odnosu na 40 mg simvastatina u snižavanju triglicerida i povišenja HDL-C-a, ali nije zadovoljio kriterije neinferiornosti na LDL-C.
In the FIELD study, a statistically significant increase was reported in the incidence of pulmonary embolism (0.7% in the placebo group versus 1.1% in the fenofibrate group; p=0.022) and a statistically non significant increase in deep vein thrombosis (placebo 1.0% 48/4900 patients) versus fenofibrate 1.4% (67/4895); p=0.074.
U ispitivanju "FIELD", prijavljeno je statistički značajno povišenje u incidenciji plućne embolije (0,7% u placebo skupini naspram 1,1% u skupini fenofibrata; p= 0,022) i statistički neznačajno povećanje duboke venske tromboze (placebo 1,0% 48/4900 bolesnika) naspram fenofibrata 1,4% (67/4895); p= 0,074.
• chest pain and feeling breathless - these may be signs of a blood clot in the lung (pulmonary embolism)
• bol u prsima i osjećaj nedostatka zraka - to mogu biti znakovi krvnog ugruška u plućima (plućna embolija)
Avoid when taking Cholib
Izbjegavajte za vrijeme primjene Choliba
Combination with itraconazole, ketoconazole, posaconazole, HIV protease inhibitors (e.g. nelfinavir), erythromycin, clarithromycin, telithromycin and nefazodone is contraindicated (see section 4.3).
Kontraindicirana je kombinacija s itrakonazolom, ketokonazolom, posakonazolom, inhibitorima proteaze HIV-a (npr. nelfinavir), eritromicinom, klaritromicinom, telitromicinom i nefazodonom (vidjeti dio 4.3).
• complications of gall stones such as colic because of stones in bile duct, infection of the bile ducts or gall bladder
• komplikacije žučnih kamenaca kao što je grčevita bol zbog kamenaca u žučnom kanalu,
• drop in haemoglobin (that carries oxygen in blood) and white blood cells- shown in tests
• pad hemoglobina (koji prenosi kisik u krvi) i bijelih krvnih stanica - vidljivo u pretragama
Lipid parameter (mmol/L)
Lipidni parametar (mmol/l)
The usual dose is recommended, except for decreased renal function with estimated glomerular filtration rate < 60 mL/min/1.73 m where Cholib is contraindicated
Preporučuje se uobičajena doza, osim kod smanjene funkcije bubrega s procijenjenom brzinom glomerularne filtracije <60 ml/min/1,73 m gdje je Cholib kontraindiciran
No effects on fertility were detected in non-clinical reproductive toxicity studies conducted with fenofibrate.
U nekliničkim ispitivanjima reproduktivne toksičnosti provedenima s fenofibratom nisu uočeni utjecaji na plodnost.
This occurrence may represent a failure of efficacy in patients with severe hypertriglyceridaemia, an induced pancreatic enzymes increase or a secondary phenomenon mediated through biliary tract stone or sludge formation with obstruction of the common bile duct.
Razlog može biti izostanak djelotvornosti u bolesnika s teškom hipertrigliceridemijom, izazvano povišenje enzima gušterače ili sekundarno zbog začepljenja žučovoda žučnim kamencima ili pijeskom.
One film-coated tablet contains, 194.7 mg of lactose (as monohydrate), 145 mg of sucrose and 0.8 mg of lecithin (derived from soya bean (E322)).
Jedna filmom obložena tableta sadrži 194,7 mg laktoze (u obliku hidrata), 145 mg saharoze i 0,8 mg lecitina (iz soje (E322)).
Concomitant administration of verapamil and simvastatin resulted in a 2.3-fold increase in plasma exposure to simvastatin acid, presumably due, in part, to inhibition of CYP 3A4.
Istodobna primjena verapamila i simvastatina rezultirala je povećanjem izloženosti simvastatinskoj kiselini u plazmi od 2,3 puta, a pretpostavlja se djelomično zbog inhibicije CYP 3A4.
Simvastatin is a substrate of the Breast Cancer Resistant Protein (BCRP) efflux transporter.
Breast Cancer Resistant Protein, BCRP) koji je efluksni transportni protein.
EU/1/13/866/001 10 film-coated tablets EU/1/13/866/002 30 film-coated tablets EU/1/13/866/005 90 film coated tablets
EU/1/13/866/001 10 filmom obloženih tableta EU/1/13/866/002 30 filmom obloženih tableta EU/1/13/866/005 90 filmom obloženih tableta
No hepatic microsomal metabolism is involved.
Nije uključen u metabolizam u jetrenim mikrosomima.
There have been reports of rhabdomyolysis (including some fatalities) in patients receiving this combination.
U bolesnika koji su primali tu kombinaciju bilo je prijava rabdomiolize (uključujući nekoliko smrtnih ishoda).
Simvastatin is an inactive lactone which is readily hydrolyzed in vivo to the corresponding beta-hydroxyacid, a potent inhibitor of HMG-CoA reductase.
Simvastatin je inaktivni lakton koji se in vivo brzo hidrolizira u odgovarajuću beta-hidroksi kiselinu, potentan inhibitor HMG-CoA reduktaze.
Thromboembolism * In the FIELD study, a statistically significant increase was reported in the incidence of pulmonary embolism (0.7% [32/4900 patients] in the placebo group versus 1.1% [53/4895 patients] in the fenofibrate group; p = 0.022) and a statistically non-significant increase in deep vein thromboses (placebo: 1.0% [48/4900 patients] versus fenofibrate 1.4% [67/4895 patients]; p=0.074).
Tromboembolija * U ispitivanju FIELD, prijavljeno je statistički značajno povećanje incidencije plućne embolije (0,7% [32/4900 bolesnika] u placebo skupini, naspram1,1% [53/4895 bolesnika] u fenofibrat skupini; p= 0,022) i statistički neznačajno povećanje duboke venske tromboze (placebo: 1,0% [48/4900 bolesnika] naspram fenofibrata 1,4% [67/4895 bolesnika]; p=0,074).
The geomean maximum plasma level (Cmax) of the inactive parent simvastatin was 2.7 ng/mL for the fixed dose combination Cholib 145 mg/20 mg tablet and 3.9 ng/mL for the co-administration of the separate 145 mg fenofibrate and 20 mg simvastatin tablets as used in the clinical program.
Geometrijska sredina maksimalne razine u plazmi (Cmax) inaktivnog ishodišnog simvastatina bila je 2,7 ng/ml za tabletu fiksne kombinacije doze Choliba 145 mg/20 mg i 3,9 ng/ml za istodobnu primjenu odvojenih tableta 145 mg fenofibrata i 20 mg simvastatina kao što je korišteno u kliničkom programu.
EU/1/13/866/003 10 film-coated tablets EU/1/13/866/004 30 film-coated tablets EU/1/13/866/006 90 film coated tablets
EU/1/13/866/003 10 filmom obloženih tableta EU/1/13/866/004 30 filmom obloženih tableta EU/1/13/866/006 90 filmom obloženih tableta
*Treatment Comparison consists of the difference between the LS-means for Feno 145 + Simva 40 an d Simva 40, as well as the corresponding 95% CI.
* Usporedba liječenja sastoji se od razlike između srednjih vrijednosti najmanjih kvadrata (LS) za feno 145 + simva 40 i simva 40, kao i odgovarajući 95%-tni CI.
Therefore, Cholib is contraindicated during breast-feeding (see section 4.3).
Stoga je Cholib kontraindiciran tijekom dojenja (vidjeti dio 4.3).
Feno 145+Simva 20 (N=493)
Parametar feno 145+simva 20 (n=493) srednja vrijednost (SD)
• HIV protease inhibitors such as indinavir, nelfinavir, ritonavir and saquinavir
• inhibitore proteaze HIV-a kao što su indinavir, nelfinavir, ritonavir i sakvinavir (lijekovi koji se koriste kod HIV-infekcija i AIDS-a)
Contraindicated with Cholib 145 mg/40 mg
Kontraindicirano s Cholibom 145 mg/40 mg
Butylhydroxyanisole (E320), lactose monohydrate, sodium laurilsulfate, starch, pregelatinised (maize), docusate sodium, sucrose, citric acid monohydrate (E330), hypromellose (E464), crospovidone (E1202), magnesium stearate (E572), silicified microcrystalline cellulose (comprised of cellulose, microcrystalline and silica, colloidal anhydrous), ascorbic acid (E300).
Butilhidroksianizol (E320), laktoza hidrat, natrijev laurilsulfat, prethodno geliran kukuruzni škrob, natrijev dokuzat, saharoza, citratna kiselina hidrat (E330), hipromeloza (E464), krospovidon (E1202), magnezijev stearat (E572), silicirana mikrokristalična celuloza (sastoji se od mikrokristalične celuloze i koloidnog, bezvodnog silicijevog dioksida), askorbatna kiselina (E300).
• you have an underactive thyroid gland (hypothyroidism)
• ako imate smanjenu aktivnost štitnjače (hipotireoza)
• you are taking hepatitis C antiviral agents such as elbasvir or grazoprevir (used to treat hepatitis
• ako uzimate antivirusne lijekove za hepatitis C kao što su elbasvir ili grazoprevir (koji se upotrebljavaju za liječenje infekcije virusom hepatitisa C)
Non-HDL-C (mmol/L)
Ne-HDL-C (mmol/l)
• increase in blood platelets count
• povećanje broja trombocita u krvi
The mechanism of the LDL lowering effect of simvastatin may involve both reduction of VLDL-C concentration and induction of the LDL receptor, leading to reduced production and increased catabolism of LDL-C. Apolipoprotein B also falls substantially during treatment with simvastatin.
Mehanizam kojim simvastatin snižava LDL može uključivati i snižavanje koncentracije VLDL kolesterola (VLDL-C) i indukciju LDL receptora, što dovodi do smanjenog stvaranja i pojačane razgradnje LDL-C-a.
• If you are already taking the following medicines: o danazol (a man-made hormone used to treat endometriosis) o ciclosporin (a medicine often used in organ transplant patients) o itraconazole, ketoconazole, fluconazole or posaconazole (medicines for fungal infections) o HIV protease inhibitors such as indinavir, nelfinavir, ritonavir and saquinavir (medicines used for HIV infection and AIDS) o glecaprevir or pibrentasvir (used to treat hepatitis C virus infection) o erythromycin, clarithromycin, or telithromycin (medicines for bacterial infections) o nefazodone (a medicine for depression)
• Ako već uzimate sljedeće lijekove:  danazol (sintetski hormon za liječenje endometrioze)  ciklosporin (lijek koji često uzimaju bolesnici s presađenim organom)  itrakonazol, ketokonazol, flukonazol ili posakonazol (lijekovi za gljivične infekcije)  inhibitore proteaze HIV-a kao što su indinavir, nelfinavir, ritonavir i sakvinavir (lijekovi koji se koriste kod HIV-infekcija i AIDS-a)  glekaprevir ili pibrentasvir (koji se upotrebljavaju za liječenje infekcije virusom hepatitisa C)  eritromicin, klaritromicin ili telitromicin (lijekovi za bakterijske infekcije)  nefazodon (lijek za depresiju)